Dr. Shui On LEUNG, the Executive Director, Chairman of the Board and Chief Executive Officer of SinoMab BioScience Limited.
Dr. Shui On LEUNG, the Executive Director, Chairman of the Board and Chief Executive Officer of SinoMab BioScience Limited (on the left) & Mr. Jing QIANG, President of SinoMab BioScience Limited (On the right).
Hong Kong, 30 December 2019 – SinoMab BioScience Limited (SinoMab BioScience), a Hong Kong Science and Technology Parks Corporation (HKSTP) partner company, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited on 12 November 2019.
SinoMab BioScience is a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. SinoMab BioScience is one of a few select biopharmaceutical companies in the Greater China Region that has full-fledged capability. The Company has built a platform with an industry chain allocation to standardise and systemically monitor the Company’s R&D, clinical trials and manufacturing process. This comprehensive platform integrates all-industry functionalities, including target identification, drug candidate development, pre-clinical research, clinical trials, clinical production, quality control and quality assurance, regulatory approval and commercial-scale production up to the commercialisation stage.
Dr. Shui On LEUNG, the Executive Director, Chairman of the Board and Chief Executive Officer of SinoMab BioScience said on the listing ceremony, “We are profoundly honoured to be the first local Hong Kong-based biopharmaceutical company listed on the Main Board of SEHK. SinoMab BioScience officially entered the Hong Kong stock market and tapped into the international capital market, marking an important milestone in the development of the Company’s development history. Looking ahead, we will expeditiously promote the commercialisation of SM03, further expand the pipeline of drugs candidates, continue discovering and developing novel drugs for the treatment of immunological diseases by leveraging our R&D capabilities, expand production scale and strengthen global businesses, striving to contribute to global and Chinese biomedical innovation.”
Mr. Albert Wong, CEO of HKSTP said, “HKSTP is proud of SinoMab BioScience’s new chapter to its public listing. The Company represents a shining example for other biomedical companies in the ecosystem that substantial value and prosperity could be added to their businesses through continuous research and development. We congratulate Dr. Leung and his team for their successful listing and wish their success would give birth to more novel products and technologies.
HKSTP strives to nurture biomedical startups by providing them with the best environment and support, as well as connecting them with market and investment opportunities. We hope to see more of our homegrown biomedical companies achieve the success that SinoMab BioScience has achieved.”
As of 22 October 2019, SinoMab BioScience has built up a product pipeline consisting of six drug candidates, including portfolio of first-in-target and first-in-class drug candidates. The most near-commercialisation candidate SM03 is clinically proven, first-in-target anti-CD22 mAb for the treatment of RA and potentially other immunological diseases. SM03 is currently in Phase III clinical trial for RA in China, and patient enrollment is aimed to be completed by the end of 2019.
Biomedical technology is one of HKSTP’s technology focus areas, with Hong Kong Science Park currently hosting more than 120 biotechnology companies who work in specialty areas such as medical devices, molecular diagnoses, stem cell therapy, regenerative medicine, Chinese herbal medicine and advanced therapeutics. HKSTP offers a range of incubation and acceleration services, such as the Incu-Bio programme, a four-year all-round programme in support of the growth of biomedical startups, funding and investment, and a host of support services such as well-equipped shared laboratories and market development services.